In 2016, there were approximately 216 million cases of malaria in 91 countries, resulting in 445 000 deaths \[[@CIT0001]\]. The World Health Organization (WHO) African Region bears the largest burden, with around 90% of the malaria cases. The WHO guidelines recommend that all suspected cases of malaria be confirmed with microscopy and/or rapid diagnostic tests. In Canada, there are on average 488 malaria cases per year across the country \[[@CIT0002]\], and approximately 1700 annually in the United States \[[@CIT0003]\]. However, in nonendemic settings such as North America, the vast majority of tests performed are negative.

Globally, the diagnosis of malaria is achieved with microscopy and rapid diagnostic tests (RDTs), or a combination of these. The WHO estimates that around 204 million patients were tested by microscopy and 269 million rapid diagnostic tests were sold in 2016 \[[@CIT0004]\]. Although the increasing use of diagnostic-based treatment rather than symptom-based treatment undoubtedly has significant benefits, it is not without limitations. Microscopy has been found to have a limit of detection (LOD) of 50--100 parasites/μL under field conditions \[[@CIT0005], [@CIT0006]\]. However, this can only be achieved when laboratory facilities are available, along with a specialized microscopist. Studies have found that the LOD varies depending on the training and experience of the microscopist \[[@CIT0007]\]. The method is labor-intensive and requires constant quality assurance. Due to these limitations, and therefore the possibility of false negatives, the Centers for Disease Control and Prevention (CDC) in the United States and Public Health Canada both recommend that 3 malaria slides be taken \[[@CIT0008], [@CIT0009]\]. This is not just an inconvenience to the patient, who may have to return the emergency room several times; it results in increased health care costs due to re-attendance and increased laboratory time.

Although RDTs have demonstrated a sensitivity and specificity \>90% for *Plasmodium falciparum* infections with \>200 parasites/μL, they cannot reliably diagnose cases with parasitemia below this level \[[@CIT0010]\]. Additionally, false-negative RDT results can occur from parasites that do not produce histidine-rich protein 2 (HRP2), a growing concern in malaria-endemic regions \[[@CIT0011]\]. Molecular testing such as polymerase chain reaction (PCR) can achieve an LOD of 1 parasites/μL with improved sensitivity, but these tests are expensive and simply not feasible without a well-equipped laboratory and expertise \[[@CIT0014]\].

Given the limitations with the current testing methods of microscopy, RDTs, and PCR, there has been interest in validating simpler nucleic acid tests (NATs) such as loop-mediated isothermal amplification (LAMP) \[[@CIT0015]\]. LAMP is a technology that was developed in 2000 that uses unique DNA polymerases and specially designed primers to amplify nucleic acid without thermocyclers \[[@CIT0020]\]. LAMP can differentiate species, and variations can even be used to detect the C580Y mutation in the propeller domain of the *kelch 13* gene, the most prevalent marker of artemisinin resistance \[[@CIT0021]\]. The LOD varies slightly depending on the exact protocol used, but it can achieve limits of detection of ≤2 parasites/μL, similar to those achieved by PCR and surpassing those of microscopy and RDTs \[[@CIT0022]\]. The *illumi*gene Malaria LAMP assay (*illumigene* M; Meridian Biosciences, Cincinatti, OH) has shown good sensitivity and specificity vs microscopy, the current gold standard \[[@CIT0015]\]. It performs well in terms of technological simplicity and cost. Commercial LAMP technology has been assessed against PCR in a number of studies, with extremely encouraging results ([Table 1](#T1){ref-type="table"}) \[[@CIT0015], [@CIT0022], [@CIT0025]\]. Given the excellent negative predictive value properties of LAMP in malaria, our group has proposed replacing the current testing algorithm, which relies on 3 microscopy tests to rule out infection, with a single LAMP test \[[@CIT0015]\]. This would improve testing turnaround time, optimize use of the emergency room, and reduce cost to the health care system.

###### 

Commercial LAMP Performance Against PCR

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Article              Commercial Kit   Specimen Analysis^b^            Location                             Sensitivity\        Specificity\
                                                                                                             (95% CI), %         (95% CI), %
  -------------------- ---------------- ------------------------------- ------------------------------------ ------------------- -------------------
  Aydin-Schmidt 2014   Eiken            Retrospective                   Zanzibar -- pre-elimination          91.5 (84.8--95.8)   100 (99.5--100)

  Hopkins 2013         Eiken            Prospective                     Uganda -- high endemicity            90.0 (85.0--94.0)   85.0 (75.0--92.0)

  Lucchi 2016          *illumigene*     Prospective and retrospective   Senegal -- low endemicity            97.2 (92.6--99.1)   93.8 (84.2--98.0)

  Marti 2015           Eiken            Prospective                     Switzerland -- returning travelers   100 (92.4--100)     100 (97.7--100)

  Polley 2013          Eiken            Prospective                     UK -- returning travelers            97.0 (89.6--99.6)   99.2 (98.1--99.7)

  Ponce 2017           *illumigene*     Prospective                     France -- returning travelers        100 (95.8--100)     98.1 (95.3--99.5)

  Rypien 2017          *illumigene*     Retrospective                   Canada -- returning travelers        97.3 (90.7--99.7)   93.8 (84.8--98.3)

  Sema 2015^a^         Eiken            Retrospective                   Ethiopia - moderate endemicity       96.8 (83.2--99.5)   84.3 (71.4--92.9)

  Tegegne 2017         Eiken            Retrospective                   Ethiopia - moderate endemicity       100 (100--100)      93.5 (86.5--100)
  --------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI, confidence interval; LAMP, loop-mediated isothermal amplification; PCR, polymerase chain reaction.

^a^Field values taken.

^b^\"Prospective\" defined as blood specimens tested within 72 hours without preservation; others considered \"retrospective\".

On a global note, if elimination is to be achieved, a diagnostic tool with a lower limit of detection is required. A recent study modeling eradication showed that reducing the limit of detection of a diagnostic test increased the detection of the asymptomatic infectious reservoir \[[@CIT0029]\]. LAMP meets this criterion, and several studies have described the role it could play in malaria elimination \[[@CIT0010], [@CIT0025], [@CIT0026], [@CIT0030], [@CIT0031]\].

Although LAMP has been shown in studies to surpass microscopy and RDTs, many studies to date have been retrospective in nature. In addition, studies have often focused on *P. falciparum* rather than all species of malaria. Our study was designed to closely reflect testing scenarios in North America. A single-center evaluation of LAMP performance against microscopy for all species of malaria in a major urban center (1.4 million people) was conducted. The primary objective of the study was to compare the clinical performance of a commercially available LAMP method (*illumigene* M) vs RDT (BinaxNOW) compared with microscopy in symptomatic patients presenting as potential cases of malaria in a nonendemic area. The secondary objective was to determine if certain clinical and epidemiological factors predicted malaria test results using regression analysis.

METHODS {#s1}
=======

Study Design, Patient Enrollment, and Ethics {#s2}
--------------------------------------------

The study design was pragmatic, containing both prospective and retrospective arms to provide an adequate distribution of all species of malaria. In the prospective arm, adult participants who underwent malaria testing were consecutively enrolled into the study from June 2017 until January 2018. Based on sample size calculation, a goal of 350 specimens was set with at least 10% overall positivity for all species of malaria. To achieve this, testing was performed on a continuous basis with interruptions only to ensure that enough positive samples were tested. Samples arriving at night were tested first thing in the morning by medical laboratory technologists using the LAMP technology. All prospectively enrolled participants had epidemiological data collected through a case history form that accompanied the specimens. Variables recorded included whether pretravel advice was received, reason for travel, country visited, symptoms, severity, whether the participant took antimalarial prophylaxis, and whether they were on treatment. In addition to the prospective arm of the study, 29 microscopy confirmed malaria specimens were retrospectively collected and included in the study. This design has been used by other studies, and it allows an adequate sample size for rare non--*P. falciparum* species \[[@CIT0032]\]. Without this, due to the otherwise prospective nature of the study, only a small number of positive specimens for these species would have been included. Five *Plasmodiumvivax* and 5 *Plasmodium ovale* frozen whole-blood specimens (at --80°C) were obtained from a large teaching hospital in Edmonton, Canada. Thirteen *Plasmodium malariae* specimens were frozen whole-blood specimens obtained from Pará, Brazil, and 6 culture-derived *Plasmodium knowlesi* (A1-H.1 clone) specimens of varying parasitemia (range, 0.1--10 000 parasite per μL) were obtained from London, United Kingdom. Retrospective specimens were thawed and underwent the same LAMP testing protocol as the prospective arm. No epidemiological data were available on retrospective specimens. Ethical approval was obtained from the Conjoint Health Research Ethics Board (REB17-2220), and privacy review from Alberta Health Services.

Routine Laboratory Testing for Malaria {#s3}
--------------------------------------

Venous whole-blood samples were collected in EDTA vacutainers from medical centers in Calgary and the surrounding area and transported to Calgary Laboratory Services (CLS). CLS is a large centralized public microbiology laboratory service covering 1.4 million people. Samples from malaria-positive patients who were initially symptomatic, treated, and then retested were included in the study. Each specimen was tested according to standard operating procedure: Giemsa-stained thick and thin peripheral blood smears and RDTs (BinaxNOW Malaria, Alere, Waltham, MA) on study participants. For the purposes of analysis, microscopy repeated 3 times from the same individual to confirm negativity was classified once only. Microscopy, RDTs, and LAMP testing were conducted in real time by the same technologist who was trained in all diagnostic tests due to personnel availability.

Malaria Testing With *illumigene* M LAMP {#s4}
----------------------------------------

*illumigene* Malaria (Meridian Biosciences, Cincinatti, OH) is a commercially available, loop-mediated amplification test that detects all species of human malaria. The assay provides a positive or negative result only and does not speciate. Medical laboratory technologists received training for the LAMP assay. Testing using LAMP occurred simultaneously with current standard operating procedure (SOP) for the duration of the study. Specimens received at night were tested by LAMP in the day shift due to technologist availability. LAMP was performed according to the manufacturer's recommendations. Complete standard operating procedures for *illumigene* are available online (<http://www.meridianbioscience.eu/media/pdf/Package%20Insert/280925_281125_MULTI_REV1215.pdf>). Samples were frozen once at --80°C for subsequent real-time PCR (RT-PCR) analysis, which was performed off-site in a blinded manner.

Discrepancy Resolution {#s5}
----------------------

Discrepant results occurred when the results of microscopy and the LAMP assay results were different. All microscopy-positive and discrepant specimens underwent RT-PCR testing at an off-site location at the Provincial Reference Laboratory in Edmonton, Canada, in a blinded manner. The RT-PCR method was clinically validated and used routinely at the reference laboratory \[[@CIT0033]\]. Concordant negative specimens were also tested by RT-PCR in Calgary, Canada.

Statistical Analysis {#s6}
--------------------

Data were tabulated in Microsoft Excel, version 16.11.1, and were analyzed using Stata, version 13.0. Crude statistical analysis of epidemiological dichotomous variables was determined using chi-square or Fisher exact statistical tests; *t* tests were used for comparison of means. Variables found to be statistically significant with initial analysis were then characterized through multivariate analysis with logistic regression. Retrospectively and prospectively collected specimens were pooled and analyzed together. Sensitivity, specificity, positive predictive rate, and negative predictive rate for LAMP were calculated against microscopy both before and after discrepant resolution with PCR. After being assessed for significance, multivariate logistic regression was utilized to calculate odds ratios. Both important variables and statistically significant ones were incorporated into the analysis. Admission status was excluded because it was a dependent variable, which was influenced by the malaria test result. Due to the small sample size of malaria-positive patients, variables were dichotomized to allow for reliable analysis. Continent visited was split into Africa and non-Africa, and reason for travel was split into those visiting friends and relatives (VFR) and non-VFR. The sample size for subanalyses was insufficient without this breakdown. As observed in the correlation matrix ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}), there was reason to believe that there was a correlation between pretravel advice and prophylaxis taken, so only a single variable, "prophylaxis taken," was utilized in the logistic analysis.

RESULTS {#s7}
=======

In the prospective arm, 350 specimens were collected from a total of 298 consecutive patients enrolled ([Figure 1](#F1){ref-type="fig"}). Two specimens were excluded due to having insufficient samples for specimen resolution, leaving 348 specimens. Fifty specimens were repeats from some of the participants who initially tested positive, as it is routine practice to monitor parasitemia during treatment. In the retrospective arm, 29 additional frozen specimens were used to supplement the analysis. The prospective and retrospective specimens were combined, so there were 377 specimens in total. Microscopy and LAMP were available on all specimens, but RDT testing was only performed on participants in the prospective arm if deemed appropriate (n = 307). Frozen specimens had prior microscopy data at the time of diagnosis. There was an initial "invalid" test rate with LAMP *illumigene* M of 3.18%; however, all of these resolved with a single repeat test.

![Flow chart of study design and initial results of malaria testing by each method. Abbreviations: LAMP, loop-mediated isothermal amplification; RDT, rapid diagnostic test.](ofy26001){#F1}

In the prospective arm, clinical and epidemiological data were analyzed based on the participant's final malaria result after discrepant resolution. Twenty-five participants out of 298 tested positive for malaria after discrepant resolution. Twenty-two out of the 25 participants who tested positive were positive by microscopy; the remaining 3 were confirmed by PCR. The median parasitemia (interquartile range) was 0.2 (1.275). The mean age in the cohort was 32.5 (95% confidence interval \[CI\], 29.9--35.0) years, and 50.7% of participants were male ([Table 2](#T2){ref-type="table"}). Fever was by far the most common symptom (265/298; 88.9%), followed by headache (124/298; 41.6%), cough (102/298; 34.3%), night sweats (96/298; 32.2%), and myalgia (92/298; 30.9%). Myalgia was statistically more common in the malaria-positive group (16/25; 64.0%) compared with the malaria-negative group (76/273; 27.8%; *P* \< .001) ([Figure 2](#F2){ref-type="fig"}). Cough was statistically less common in the malaria-positive group (4/25; 16.0%) compared with the malaria-negative group (98/273; 35.9%; *P* = .047). Malaria-positive patients were more likely to be admitted than those who tested negative (*P* \< .001). For every year increase in age, the odds of testing positive for malaria decreased by 6% (odds ratio \[OR\], 0.94), which was statistically significant (95% CI, 0.91--0.98). The odds of testing positive for males was slightly lower than females (OR, 0.60; 95% CI, 0.18--1.98), but this was not statistically significant. Participants traveling to Africa were significantly more likely to test positive for malaria (OR, 18.90; 95% CI, 4.81--74.48) compared with those visiting another location. There was no difference in the odds for those visiting friends and relatives compared with those traveling for other reasons (OR, 0.88; 95% CI, 0.27--2.89). Antimalarial prophylaxis was protective, with the odds ratio for those taking it being 0.17 (95% CI, 0.02--1.48), but this was not statistically significant. Evidence of effect measure modification (EMM) was looked for between those taking prophylaxis and also visiting Africa, but none was observed. In addition, EMM was assessed for those taking prophylaxis and also in the VFR group, but the sample size was insufficient to perform the analysis.

###### 

Comparison of Clinical and Epidemiological Characteristics of Study Participants According to their Malaria Test Outcome (n = 298)

                                                    Total               Malaria Positive    Malaria Negative    *P* Value^a^
  ------------------------------------------------- ------------------- ------------------- ------------------- --------------
  No. of patients                                   298                 25                  273                 
  Age, mean (95% CI), y                             32.5 (29.9--35.0)   25.2 (18.3--32.1)   33.1 (30.5--35.8)   .089^b^
  Male, No. (%)                                     151 (50.7)          13 (52.0)           138 (50.5)          .890^e^
  Parasitemia, median (IQR)                                             0.2 (1.275)                             
  Pretravel advice (n = 208),^c^ No. (%)            69 (33.2)           2 (11.8)            67 (35.1)           .061^f^
  Malaria prophylaxis taken (n = 234),^c^ No. (%)   40 (17.1)           2 (9.1)             38 (17.9)           .385^f^
  Reason for travel,^d^ No. (%)                                                                                 
  Business                                          15 (5.0)            1 (4.0)             14 (5.1)            1.000^f^
  Not recorded                                      26 (8.7)            2 (8.0)             24 (8.8)            1.000^f^
  Visiting friends/relatives                        129 (43.3)          10 (40.0)           119 (43.6)          .692^e^
  Volunteer                                         1 (0.3)             1 (4.0)             0                   .085^f^
  New immigrant                                     32 (10.7)           6 (24.0)            26 (9.5)            .038^f^
  Tourism                                           89 (29.9)           4 (16.0)            85 (31.1)           .111^f^
  Visitor to Canada                                 6 (2.0)             1 (4.0)             5 (1.8)             .414^f^
  Continent visited (n = 287),^c^ No. (%)                                                                       
  Non-Africa                                        186 (64.8)          4 (16.0)            182 (69.5)          
  Africa                                            101 (35.2)          21 (84.0)           80 (30.5)           \<.001^f^
  Symptoms,^d^ No. (%)                                                                                          
  Fever                                             265 (88.9)          23 (92.0)           242 (88.7)          .704^f^
  Night sweats                                      96 (32.2)           8 (32.0)            88 (32.2)           .862^e^
  Myalgia                                           92 (30.9)           16 (64.0)           76 (27.8)           \<.001^e^
  Headache                                          124 (41.6)          13 (52.0)           111 (37.2)          .361^e^
  Cough                                             102 (34.3)          4 (16.0)            98 (35.9)           .047^f^
  Sore throat                                       66 (22.1)           2 (8.0)             64 (23.4)           .080^f^
  Diarrhea                                          66 (22.1)           5 (20.0)            61 (22.3)           .808^f^
  Other                                             8 (2.7)             2 (8.0)             6 (2.2)             .148^f^
  Pre-employment                                    4 (1.3)             0                   4 (1.5)             1.000^f^
  Not recorded                                      12 (4.0)            0                   12 (4.4)            .608^f^
  New immigrant screen                              4 (1.3)             0                   4 (1.5)             1.000^f^
  Admitted (n = 295),^c^ No. (%)                    47 (15.9)           12 (50.0)           35 (12.9)           \<.001^e^

Abbreviations: CI, confidence interval; IQR, interquartile range.

^a^ *P* value compares malaria-positive with malaria-negative group, missing values excluded.

^b^ *T* test of means.

^c^No. is less than the grand total due to missing data; percentages were calculated excluding missing data and statistical tests excluding missing data.

^d^Total does not add up to 100 as participants reported more than 1 symptom.

^e^Chi-square test.

^f^Fisher exact test.

![Odds ratio (OR) and 95% confidence interval (CI) for clinical and epidemiological characteristics among study participants for malaria-positive versus malaria-negative patients. ORs and 95% CIs enumerated on the x-axis were calculated using multivariate logistic regression.](ofy26002){#F2}

Data were analyzed both including and excluding retrospective specimens. For the prospective arm, when repeat testing on the same participant was included, 57 specimens tested positive by LAMP, whereas 51 tested positive by microscopy ([Table 3](#T3){ref-type="table"}). For microscopy-positive specimens, 38 tested positive for *P. falciparum*, 7 for *P. vivax*, 6 for *P. ovale*, and none for *P. malariae* or *P. knowlesi*; the remainder tested negative. Due to repeat testing of malaria-positive patients, a test positivity rate of 14.7% was obtained in this study. Surveillance data in Calgary from 2013--2018 and excluding repeat testing within 2 months of an index revealed a test positivity rate of 4.4% (unpublished data) used to calculate the PPV and NPV. In the prospective arm, LAMP had a sensitivity of 98.1% (95% CI, 90.0%--100%) and a specificity of 97.6% (95% CI, 95.2%--99.1%) vs microscopy before discrepant resolution for all samples. Based on a prevalence of 4.4%, the positive predictive value (PPV) was 65.3%, and the negative predictive value (NPV) was 99.9%. Seven specimens were negative with microscopy but tested positive with LAMP. One specimen was positive with microscopy but negative with LAMP. All specimens, both discordant and concordant, were tested by RT-PCR for confirmation. Discrepant resolution confirmed that the 7 false-positive specimens by LAMP tested positive by RT-PCR ([Table 4](#T4){ref-type="table"}). One false-negative specimen by LAMP tested negative by RT-PCR. After discrepant resolution, LAMP had a sensitivity of 100% (95% CI, 93.9%--100%) and a specificity of 100% (95% CI, 98.7%--100%) vs microscopy. The PPV and NPV were both 100%. For 1 negative specimen by LAMP and RT-PCR, only *P. ovale* gametocytes were found.

###### 

Performance of *illumigene* M Assay vs Microscopy on Returning Travelers in the Prospective Arm Before and After Discrepant Resolution by RT-PCR (n = 348)

  Before Discrepant Resolution   Microscopy   After Discrepant Resolution   PCR                                                                            
  ------------------------------ ------------ ----------------------------- ------------- ------------------------------ ----------- ---------- ---- ----- -----
  LAMP                           Positive     50                            7             57                             LAMP        Positive   57   0     57
                                 Negative     1                             290           291                                        Negative   0    291   291
                                 Total        51                            297           348                                        Total      57   291   348
                                 Percentage   95% CI, %                                   Percentage                     95% CI, %                         
  Sensitivity                    98.1         90.0--100                     Sensitivity   100                            93.7--100                         
  Specificity                    97.6         95.2--99.1                    Specificity   100                            98.7--100                         
  Positive predictive value^a^   65.3                                                     Positive predictive value^a^   100                               
  Negative predictive value^a^   99.9                                                     Negative predictive value^a^   100                               

Abbreviations: CI, confidence interval; LAMP, loop-mediated isothermal amplification; PCR, polymerase chain reaction; RT-PCR, real-time polymerase chain reaction.

^a^Based on a prevalence of 4.4%.

###### 

Results of Discrepant Resolution by Sample Number (n = 8)

  Sample Number   Microscopy       *illumigene* M   Alternate PCR   Final
  --------------- ---------------- ---------------- --------------- ----------------------------------
  018             Neg              Pos              Pos             True positive -- *P. falciparum*
  035             Neg              Pos              Pos             True positive -- *P. falciparum*
  068             Neg              Pos              Pos             True positive -- *P. falciparum*
  095             Neg              Pos              Pos             True positive -- *P. vivax*
  112             Neg              Pos              Pos             True positive -- *P. falciparum*
  122             Po gametocytes   Neg              Neg             True negative
  253             Neg              Pos              Pos             True positive -- *P. falciparum*
  265             Neg              Pos              Pos             True positive -- *P. falciparum*

Abbreviation: PCR, polymerase chain reaction; Po, plasmodium ovale.

When including retrospective specimens, an additional 5 *P. vivax*, 5 *P. ovale*, 13 *P. malariae*, and 6 *P. knowlesi* specimens were included, so that in total by microscopy there were 38 *P. falciparum* specimens, 12 *P. vivax*, 11 *P. ovale*, 13 *P. malariae*, and 6 *P. knowlesi* specimens, with the remainder being negative ([Table 5](#T5){ref-type="table"}). With retrospective specimens included, LAMP had a sensitivity of 98.8% (95% CI, 93.2%--100%) and a specificity of 97.6% (95% CI, 95.2%--99.1%) vs microscopy. After discrepant resolution, LAMP had a sensitivity of 100% (95% CI, 95.8%--100%) and a specificity of 100% (95% CI, 98.7%--100%). There were no additional discrepancies following inclusion of retrospective specimens.

###### 

Performance of *illumigene* M Assay vs Microscopy on Returning Travelers in the Prospective and Retrospective Arms Combined (n = 377) Before and After Discrepant Resolution

  Before Discrepant Resolution   Microscopy   After Discrepant Resolution   PCR                                                                                    
  ------------------------------ ------------ ----------------------------- ----------- ------------------------------ ------ ----------- ------------ ----------- -----
  LAMP                           Positive     79                            7           86                             LAMP   Positive    86           0           86
                                 Negative     1                             290         291                                   Negative    0            291         291
                                 Total        80                            297         377                                   Total       86           291         377
                                              Percentage                    95% CI, %                                                     Percentage   95% CI, %   
  Sensitivity                    98.8         93.2--100                                 Sensitivity                    100    95.8--100                            
  Specificity                    97.6         95.2--99.1                                Specificity                    100    98.7--100                            
  Positive predictive value^a^   65.5                                                   Positive predictive value^a^   100                                         
  Negative predictive value^a^   100                                                    Negative predictive value^a^   100                                         

Abbreviations: CI, confidence interval; LAMP, loop-mediated isothermal amplification; PCR, polymerase chain reaction.

^a^Based on a prevalence of 4.4%.

The performance of RDT compared with microscopy was evaluated (n = 307) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). After discrepant resolution using RT-PCR, the sensitivity was 83.3% (95% CI, 58.6%--96.4%) and specificity was 96.2% (95% CI, 93.2%--98.1%). These results correlated with a PPV of 50.2% and an NPV of 99.2%. The species-specific performance of LAMP after discrepant resolution is shown in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}.

DISCUSSION {#s8}
==========

The commonest reason for travel was recent immigrants traveling to visit friends and relatives abroad. These individuals have been found in other studies to stay in endemic areas for longer, are more likely to stay in local houses, so they are more exposed to mosquitos, and are less likely to seek pretravel advice and antimalarial prophylaxis \[[@CIT0034]\]. The patient cohort here represents a typical population presenting with the symptoms of malaria. As a result, this study is generalizable to urban centers with a large immigrant population across North America and Europe. Although numerous studies have examined the role of LAMP for the diagnosis of malaria in both the nonendemic and endemic settings, this is the first evaluation of LAMP in a "real-time" prospective trial in returning travelers to North America. A recent meta-analysis found that LAMP appears to have excellent sensitivity against PCR \[[@CIT0035]\]. Due to its limit of detection, LAMP is thought to be particularly useful in diagnosing patients with a low parasitemia below the LOD of microscopy \[[@CIT0026]\]. It has several advantages over other molecular tests: simple to use, no major capital equipment needs, and limited training needed \[[@CIT0016], [@CIT0020], [@CIT0036]\]. Laboratory technologists were trained in *illumigene* M, and they were able to perform it without difficulty in under an hour once they received the specimen.

Currently, the CDC recommendation for malaria testing is to release an RDT result as a preliminary result and then repeat thick and thin films every 6 to 8 hours on average 3 times to ensure that no parasites are present \[[@CIT0009]\]. This is accompanied by a significant labor cost in both the laboratory and in repeated emergency room use. A previous study from our group proposed a new testing algorithm for malaria with LAMP as the firstline diagnostic test \[[@CIT0015]\]. In the nonendemic setting, the proportion of malaria tests that are positive is relatively small. Repeated testing of patients without malaria based on existing algorithms results in additional costs to the laboratory and hospital. We estimated from this study that a single LAMP test with a high NPV would lead to a laboratory cost savings of up to USD\$13 per malaria test in a nonendemic setting. Further savings for the hospital may be possible resulting from the earlier discharge of the patient from the emergency room or doctor\'s office. Multiple studies have found that LAMP had an excellent NPV compared with PCR. However, they are often retrospective, do not run continuously, and/or commonly have a small number of non--*P. falciparum* species included.

A strength of the study is that all species of malaria were tested and correctly identified, which is essential if this test is to be used routinely. The study was prospective in nature and ran continuously in real time for 8 months to reflect current practice, albeit supplemented with retrospective specimens. Technologists were easily trained and were able to complete testing with *illumigene* M without supervision. This has potential advantages after-hours as technologists may not be experienced with reading the thick films required to ultimately rule out infection. Based on the LAMP sensitivity and NPV (100%) found in this study, patients presenting after-hours who test negative can safely be discharged home within 1 hour of specimen receipt at the laboratory ([Figure 3](#F3){ref-type="fig"}). The lower sensitivity of RDT (83.3%) in this study does not permit this confidence, especially for non--*P. falciparum* species, for which it fails more routinely to detect infection. Previously, the time to final reading of the thick film (where sensitivity is achieved) was 9 to 24 hours, depending on specialist technologist availability, because of the lack of confidence in the RDT result. The ability to discharge patients leads to a cost savings for the health facility because patients do not have to re-attend for repeat microscopy smears.

![Comparison of a traditional malaria testing algorithm with the novel algorithm proposed in this study. Abbreviations: LAMP, loop-mediated isothermal amplification; RDT, rapid diagnostic test.](ofy26003){#F3}

A limitation of this study is that the same technologist often performed LAMP, microscopy, and RDT testing for each specimen. It was not feasible to have multiple technologists available who could perform testing, so consequently operators were not blinded to other results. This may have introduced some misclassification bias. For discordant results, PCR testing occurred off-site and operators were blinded, thereby reducing misclassification bias for the most important results. Also, although *P. knowlesi* samples were contrived from a lab strain, LAMP has been able to detect patient samples on dried blood spots by our group (our unpublished observations) and patient whole-blood samples by others (Martin et al., unpublished data, 2018).

A limitation of the *illumigene* M platform is that it does not identify the species of malaria. This is not essential as a rapid screening test. Positive LAMP tests can be followed up with microscopy to determine species and parasitemia. An "invalid" rate of 3.18% was observed. The reasons for this are unclear (possibly due to high parasitemia, DNA amplification inhibitor, delay in the extraction process), but this study did have a smaller proportion of invalid results compared with other relevant studies \[[@CIT0015], [@CIT0030]\].

In this study, invalid results resolved with single repeated testing; however, they caused a delay in diagnosis. Specimens that did not resolve with repeated testing would require an alternative method to be used.

In a nonendemic setting where the prevalence of malaria in returning travelers is relatively low, LAMP is able to rule out malaria with a faster turnaround time without the need for repeat testing. A novel, highly sensitive testing algorithm for malaria screening with associated cost savings in the nonendemic setting is proposed.

Supplementary Data {#s9}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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